Analyses are based on patients with month 6 and month 12 measurements of 25-hydroxyvitamin D. Group comparisons are adjusted for age, sex, treatment, time of follow-up, and T2 lesion score at baseline. The graphs show the probability of conversion to clinically definite multiple sclerosis (CDMS) after 12 months (A); the cumulative number of new active lesions on brain magnetic resonance imaging (B); the percentage change in T2 lesion volume from year 1 to year 5 on brain magnetic resonance imaging (C); and percentage change in brain volume from year 1 to year 5 (D). The error bars indicate the standard error of the mean (SEM).
A, Rate ratio of new active lesions on brain magnetic resonance imaging up to year 5. B, Change of T2 lesion volume on brain magnetic resonance imaging from year 1 to year 5 by quintiles of serum 25-hydroxyvitamin D (25[OH]D). C, Annualized change in Expanded Disability Status Scale (EDSS) score from 6 months to year 5 by quintiles of serum 25(OH)D. Analyses as in Figure 1. The error bars indicate 95% CIs, with the lowest quintile used as reference.aP = .02.bP = .008.cP = .001.dP = .004.eP = .03.
eTable 1. BENEFIT Participants According to Changes in EDSS Scores Between Baseline and 6 Months
eTable 2. Selected Characteristics of Patients in BENEFIT With 25(OH)D Measurements at Months 6 and 12 by Level of the Average of Season-Adjusted 25(OH)D at Baseline, 6 Months, and 12 Months
eTable 3. HRs for Conversion to MDMS and CDMS for 50-nmol/L (20-ng/mL) increase in 25(OH)D
eTable 4. MS Activity and Vitamin D by Treatment Group: RRs for New Active MRI Lesions and MS Relapses According to a 50-nmol/L (20-ng/mL) Increment in Serum 25(OH)D LevelseTable 5. Disease Progression and Vitamin D Levels by Treatment Group: Relative Annual Change Percentage in T2 Lesion Volume and Brain Volume as well as Change of EDSS With 95% Confidence Intervals for a 50-nmol/L (20-ng/mL) Increment in Serum 25(OH)D
eFigure 1. Unadjusted Serum 25(OH)D Levels by Visit
eFigure 2. Unadjusted and Adjusted 25(OH)D Levels by Season
eFigure 3. Hazard Ratios for Conversion to MDMS (A) or CDMS (B) by Quintiles of Serum 25(OH)D
eFigure 4. Rate Ratio of Relapses up to Year 5 by Quintiles of Serum 25(OH)D
eFigure 5. Percentage Change of Brain Volume From Year 1 to Year 5 by Quintiles of Serum 25(OH)D
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ascherio A, Munger KL, White R, et al. Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurol. 2014;71(3):306–314. doi:10.1001/jamaneurol.2013.5993
It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes.
To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome).
Design, Setting, and Participants
The Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment study was a randomized trial originally designed to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically isolated syndrome. Serum 25(OH)D concentrations were measured at baseline and 6, 12, and 24 months. A total of 465 of the 468 patients randomized had at least 1 25(OH)D measurement, and 334 patients had them at both the 6- and 12-month (seasonally asynchronous) measurements. Patients were followed up for 5 years clinically and by magnetic resonance imaging.
Main Outcomes and Measures
New active lesions, increased T2 lesion volume, and brain volume on magnetic resonance imaging, as well as MS relapses and disability (Expanded Disability Status Scale score).
Higher 25(OH)D levels predicted reduced MS activity and a slower rate of progression. A 50-nmol/L (20-ng/mL) increment in average serum 25(OH)D levels within the first 12 months predicted a 57% lower rate of new active lesions (P < .001), 57% lower relapse rate (P = .03), 25% lower yearly increase in T2 lesion volume (P < .001), and 0.41% lower yearly loss in brain volume (P = .07) from months 12 to 60. Similar associations were found between 25(OH)D measured up to 12 months and MS activity or progression from months 24 to 60. In analyses using dichotomous 25(OH)D levels, values greater than or equal to 50 nmol/L (20 ng/mL) at up to 12 months predicted lower disability (Expanded Disability Status Scale score, −0.17; P = .004) during the subsequent 4 years.
Conclusions and Relevance
Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
Multiple sclerosis (MS) is a common cause of neurological disability in young adults.1 Most patients experience bouts of inflammatory demyelination (relapsing-remitting MS) followed years later by treatment-resistant disease progression and brain atrophy.2 A higher MS risk in individuals with low vitamin D intake3 or low circulating 25-hydroxyvitamin D (25[OH]D),4-7 as well as an inverse correlation between vitamin D status and MS activity, have been reported8-11 and suggest that vitamin D is related to the disease process that leads to and perpetuates MS. However, previous clinical studies were conducted among patients with variable disease duration and could not determine whether low vitamin D is a consequence of MS activity12 or whether vitamin D levels early in the disease course contribute to predict long-term progression and disability. Because the prevalence of vitamin D insufficiency (25[OH]D<50 nmol/L [20 ng/mL]) is high,13 supplementation could potentially benefit a large proportion of patients with MS.
Therefore, we aimed to determine whether vitamin D status early in the disease process influenced long-term disease course among participants in the Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) trial.
BENEFIT was originally designed to compare early vs delayed interferon beta-1b (IFNB-1b; Betaseron) treatment in patients with a diagnosis of clinically isolated syndrome (CIS). Between February 2002 and June 2003, patients from 18 European countries, Israel, and Canada were enrolled in 98 centers. Patients presenting with a first episode of neurological dysfunction highly suggestive of MS with a minimum of 2 clinically silent lesions on magnetic resonance imaging (MRI) were randomized in a 5:3 ratio to receive either IFNB-1b, 250 μg, (n = 292) or placebo (n = 176) subcutaneously every other day for 2 years or until a second clinical event occurred and the diagnosis of clinically definite MS (CDMS) could be established. All patients were then eligible to enter a prospectively planned follow-up phase with open-label IFNB-1b up to a maximum of 5 years after randomization. Details of the study results and design have been published elsewhere.14-16
This study was approved by the Harvard School of Public Health institutional review board. Participants in the BENEFIT trial provided written informed consent; our study used de-identified data and biological samples, without direct contact with BENEFIT participants.
Levels of 25(OH)D were measured in serum samples collected at baseline and 6, 12, and 24 months. Samples were shipped to the central laboratory within 3 days of being drawn and then maintained at −20°C until further analysis. Only samples with a minimum of 2 mL serum were used for this study, resulting in 465 patients (out of 468 enrolled) with at least 1 25(OH)D measurement, 417 with 2 or more, 396 with 3 or more, and 303 with all 4 measurements. Serum 25(OH)D was measured using an enzyme-linked immunosorbent assay (Immunodiagnostic Systems Inc). The average intra-assay coefficient of variation derived from blind quality control samples was 4.4% and the average interassay coefficient of variation was 11.7%. As expected, serum 25(OH)D levels varied by season (eFigure 1 in Supplement). The baseline level of 25(OH)D was strongly correlated with levels at 12 (Spearman correlation, r = 0.61) and 24 months (r = 0.60) and moderately correlated with the opposite season levels at 6 months (r = 0.30). Because the primary purpose of the study was to estimate the effects of long-term average 25(OH)D levels, seasonal variations were removed as previously described.4
Serum 25(OH)D was treated as a time-dependent variable using at each point the average of all previous values. Because the seasonally synchronous baseline, 12-month, and 24-month samples could provide a biased estimate of the year-round vitamin D status, most analyses were restricted to patients who had 25(OH)D measured at both 6 and 12 months. The 12-month level was preferred to the baseline level because the latter had to happen within 60 days after the start of the CIS and thus could have been affected by the acute inflammatory process. To minimize the possibility that lower 25(OH)D levels were a consequence of MS severity rather than its cause, we also related the cumulative average 25(OH)D levels at 12 months with outcomes between 12 and 60 months or between 24 and 60 months (ie, leaving a 1-year lag between 25[OH]D measurement and assessment of MS activity or progression). Three sets of analyses were planned a priori, each with a different specification of serum 25(OH)D levels: (1) continuous to determine the overall linear trend; (2) quintiles to explore the dose response; and (3) categorical with the following predefined intervals: less than 25 nmol/L; 25 to less than 50 nmol/L; 50 to less than 75 nmol/L; and greater than or equal to 75 nmol/L. Because of sparse data in the extreme groups, these latter categories were collapsed to less than 50 nmol/L vs greater than or equal to 50 nmol/L.
Three outcome categories were analyzed using clinical and MRI assessments: time to a definite diagnosis of MS, MS activity, and MS progression. A specially trained evaluating physician conducted all standardized neurological evaluations and determined the Expanded Disability Status Scale (EDSS) score.17 Relapses were assessed and defined in accordance with established guidelines.18 Magnetic resonance images were conducted every 3 months in the first year and then at 18, 24, 36, 48, and 60 months. All MRIs were quality controlled and centrally evaluated by the Image Analysis Center in Amsterdam (lead by F.B.). Definite diagnosis of MS was determined by clinical and MRI criteria (McDonald et al MS [MDMS] criteria)19 and by purely clinical criteria (modified Poser et al criteria, referred to as CDMS).18 Activity of MS was assessed as the number of relapses and the number of new active lesions on brain MRI (defined as new T2 lesions, new gadolinium+ lesions or enlarging T2 lesions). Magnetic resonance imaging markers of progression were the percentage change of T2 lesion volume and the percentage change of brain volume. The change in brain volume was measured in the Magnetic Resonance Image Analysis Center in Basel (lead by E-W.R.) using the Structural Image Evaluation using Normalization of Atrophy method,20 focusing on the central cerebral volume. Owing to rigorous criteria with respect to scan quality and brain coverage, approximately 20% of the images were excluded from brain-volume analysis. Considering that the baseline MRI was obtained at a time of acute inflammation (the CIS) with a high probability of partial spontaneous resolution of MRI pathology in the first year after the CIS21 and considering the possible effect of resolution of edema and cellular infiltrates on atrophy measurements (pseudoatrophy) after initiation of anti-inflammatory MS therapies,22 the month 12 visit was used as the primary reference point for the analysis of the percentage change in T2 volume and brain volume. Clinically, progression was assessed by changes of the EDSS score over time. Because spontaneous recovery of neurological deficits due to the CIS was expected after the baseline visit16 (eTable 1 in Supplement), month 6 was used as the primary reference point for analysis of the EDSS score outcome.
McDonald et al MS and CDMS were analyzed using a Cox proportional hazards regression model. Because many conversions occurred during the first 6 months, these results are strongly dependent on 25(OH)D levels measured close to the time of the first clinical event, which may not accurately reflect a patient’s average vitamin D status.4 Therefore, we also examined the relation between 25(OH)D levels and the rate of conversion to MS using as baseline the 6-month or 12-month visit. Other outcomes, including relapse rate, number of new active MRI lesions, change in T2 lesion volume, percentage brain loss, and change in EDSS score, were analyzed using a generalized mixed-effects model treating the patient as a random effect. The relapse rate was modeled as a binary variable indicating whether a relapse occurred on a given day, the number of new active MRI lesions was modeled as a count variable, and the other outcomes were modeled as continuous variables. The within-subject data were adjusted for any serial correlation that was present.
All the analyses were adjusted for sex, age at baseline, initial group of randomization (IFNB-1b or placebo), baseline T2 lesion score (the logarithm of the number of T2 lesions), and the type of CIS (monofocal vs multifocal). Further adjustments for baseline body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and use of steroids for the initial clinical event did not materially change the results and were therefore omitted. Because no significant interactions were present between 25(OH)D levels and either randomization group (initial placebo or initial IFNB-1b) or sex in any of the previously mentioned analyses, only aggregate results are shown (results by treatment group are included in the Supplement). Of note, patients randomized to initial treatment had a mean exposure of 1387 days to IFNB-1b, whereas patients randomized to initial placebo were exposed for a mean of 498 days to placebo and for a mean of 1016 days to IFNB-1b. P values were not corrected for multiple comparisons.
Patients with higher 25(OH)D levels tended to have a younger age, a lower BMI, a lower number of T2 lesions, and a higher brain volume at the CIS but were otherwise similar to those with lower levels (Table 1). Patient characteristics in the subgroup with months 6 and 12 measurements did not differ from these results (eTable 2 in Supplement). The distribution of 25(OH)D levels by visit and by season is shown in eFigure 1 and eFigure 2 in Supplement).
During the 5 years of follow-up, 377 patients (81.3%) converted to MDMS and 216 (46.6%) converted to CDMS. The hazard of conversion decreased with increasing serum 25(OH)D, more strongly after 6 months, and among patients with 25(OH)D measures at both 6 and 12 months, among whom the hazard of conversion decreased by more than 50% for a 50-nmol/L (20-ng/mL) increase in 25(OH)D (eTable 3 in Supplement). Results by treatment group are in eTable 3 and by quintiles in eFigure 3 in Supplement. Mean serum 25(OH)D levels at 12 months contributed to predict subsequent conversions to MDMS (P = .02) and CDMS (P = .05) (Figure 1A).
The rate of occurrence of new active lesions decreased with increasing serum 25(OH)D (Table 2); this inverse association was particularly strong for patients with both 6- and 12-month 25(OH)D measurements, among whom a 50-nmol/l increase in the average 25(OH)D at up to 12 months predicted a 57% lower rate between 12 and 60 months and a 63% lower rate between 24 and 60 months (Table 2). Significant inverse associations were also observed in categorical analyses (dichotomous in Figure 1B; quintiles in Figure 2A). Results by treatment group are in eTable 4 in Supplement.
On average, patients in BENEFIT experienced 0.2 relapses per year. Overall, the relapse rate decreased by 27% (not significant) for a 50-nmol/L increment in 25(OH)D (Table 2). This association was stronger among patients with 25(OH)D measures at both 6 and 12 months; in this group, a significantly lower relapse rate with increasing serum 25(OH)D was observed after 12 months. No significant associations were found in analyses based on categorical 25(OH)D level (eFigure 4 in Supplement).
Higher levels of 25(OH)D were associated with less T2 lesion volume accumulation over time; the relative decrease in T2 lesion volume for a 50-nmol/L increase in 25(OH)D was 20% per year (P < .001) (Table 3). Restriction to patients with both 6-month and 12-month 25(OH)D measures tended to strengthen the results. Results by treatment group are in eTable 5 in Supplement. Results by dichotomous 25(OH)D are shown in Figure 1C and those by quintiles in Figure 2B.
A 50-nmol/L (20-ng/mL) increase in 25(OH)D was associated with a 0.27% lower rate of brain loss (P = .12) (Table 3). In analyses excluding patients missing the 6- or 12-month 25(OH)D levels, the overall 25(OH)D-related annual difference in brain-volume loss for a 50-nmol/L (20-ng/mL) increase in 25(OH)D was 0.41% (P = .07). Results by treatment group are in eTable 4 (Supplement). In analyses with dichotomous 25(OH)D, the percentage loss in brain volume was lower among patients with 25(OH)D concentrations at 12 months greater than or equal to 50 nmol/L (20 ng/mL) compared with those less than 50 nmol/L (20 ng/mL) (0.34%; P = .005; Figure 1D). Analyses by quintiles revealed an unexpected J-shaped relation (higher brain volume in the lowest quintile (eFigure 5 in Supplement).
A 50-nmol/L increase in 25(OH)D levels was associated with a reduction of 0.16 steps in the average EDSS score (P = .11). Results restricted to patients with measured 6- and 12-month 25(OH)D measures were similar (Table 3). The annualized change in EDSS score was lower among patients with serum 25(OH)D greater than or equal to 50 nmol/L compared with those less than 50 nmol/L (−0.17; P = .004), as well as in patients in the highest quintiles compared with those in the lowest quintile (Figure 2C).
In this large prospective investigation, we found that average serum 25(OH)D levels in the first 12 months following a CIS strongly predicted MS activity and progression during the subsequent 4 years. By the end of the follow-up at 60 months, those patients with serum 25(OH)D concentrations greater than or equal to 50 nmol/L had a 4-times lower change in T2 lesion volume, a 2-fold lower rate of brain atrophy, and lower disability than those below 50 nmol/L. Although associations were generally stronger for MRI than for clinical outcomes, the latter were still remarkable considering the overall low rate of relapses (0.2 per year) and small EDSS score change (median change, 0.0) in BENEFIT. Moreover, the profound association of 25(OH)D levels with MRI measures of disease activity and progression is of particular clinical relevance for patients with CIS in whom the prognostic value of MRI pathology for the development of long-term disability has been demonstrated.23,24 It is also noteworthy that the inverse relation of 25(OH)D levels with development of MS, relapses, and MRI measures was observed in a population being treated with IFNB-1b, which had a considerable impact on these outcomes in the present study.14,16,21
Distinctive strengths of this study include the longitudinal design, recruitment of all patients at the time of CIS, repeated measurement of serum 25(OH)D levels, the large number of participants, standardized treatment (early vs late IFNB-1b), and rigorous clinical and MRI assessment of all patients during a 5-year period.16 Because serum 25(OH)D levels strongly depend on time spent outdoors, which can in turn be affected by MS activity, reverse causation could have explained the cross-sectional or short-term inverse associations between serum 25(OH)D concentrations and MS activity previously reported.9-12,25,26 The robustness of our results in analyses leaving a 1-year lag time between the last serum 25(OH)D measurement and assessment of MS outcomes provides evidence that low vitamin D was not a consequence of the disease process itself but rather its predictor.
Our study also had some limitations. First, almost all patients in our study were white individuals of European ancestry, thus limiting generalizations to individuals of other races or ethnicities. Second, most participants were eventually treated with IFNB-1b—although uniform treatment is an important advantage, our results may not apply to patients treated with different drugs. Third, although a clear dose response was observed for the most sensitive MRI outcomes, there was no evidence of a ceiling effect, and it is thus possible that the potential benefits of vitamin D are fully reached only at serum 25(OH)D concentrations greater than the still moderate level observed in the highest quintile of participants in BENEFIT (median, 69 nmol/L or 27.6 ng/mL).
The combined results of previous epidemiological studies relating serum 25(OH)D levels to MS risk4-6 and those of the present investigation imply that either serum 25(OH)D levels directly affect the disease process before and after the onset of symptoms or they act as a prognostic marker. The inverse association between vitamin D and MS outcomes could be explained if both were affected by a common factor or confounder. Among healthy individuals, the main predictors of 25(OH)D levels, besides vitamin D intake, are exposure to ultraviolet light, BMI, and genetic factors.27-29 Ultraviolet light has some immunosuppressive effects not mediated by vitamin D,30,31 which could contribute to the associations reported here, but the inverse association between vitamin D intake and MS risk3 and the beneficial effects of vitamin D in animal models of MS32,33 favor a role of vitamin D itself. Differences in BMI are also unlikely to explain our results because adjustment for this factor was inconsequential. Finally, genetic effects28,29 are too small to account for the strong inverse associations reported here.34 As in all observational studies, a role of unknown factors cannot be excluded. Results of 3 small double-blind randomized trials have been inconsistent,35-37 but these studies were not powered to determine the efficacy of vitamin D on MS outcomes.
The results of our study reveal a robust prognostic value of vitamin D levels measured early in the MS course and converge with previous epidemiological and biological evidence supporting a protective effect of vitamin D on the disease process underlying MS,38 and thus the importance of correcting vitamin D insufficiency, which affects about 50% of patients with MS in Europe39 and 20% in the United States.11,40 However, further investigations are needed to determine the optimal levels of vitamin D and whether results apply to different races or ethnicities, to patients with the secondary or primary progressive course of MS, or in combination with drugs other than IFNB-1b.
In summary, in this large longitudinal study among patients with CIS randomized to early vs late treatment with IFNB-1b, we found that higher serum 25(OH)D levels robustly predicted a lower degree of MS activity, MRI lesion load, brain atrophy, and clinical progression during the 5 years of follow-up. Although controlled studies currently under way41 may provide more definitive answers as to the therapeutic value of further increasing already adequate vitamin D levels, our results suggest that identification and correction of vitamin D insufficiency has an important role in the early treatment of MS.
Corresponding Author: Alberto Ascherio, MD, DrPH, Harvard School of Public Health, 655 Huntington Ave, Building 2, 3rd Fl, Boston, MA 02115 (firstname.lastname@example.org).
Accepted for Publication: November 22, 2013.
Published Online: January 20, 2014. doi:10.1001/jamaneurol.2013.5993.
Author Contributions: Dr Ascherio had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Kappos and Pohl contributed equally.
Study concept and design: Ascherio, Munger, Polman, Freedman, Montalban, Pleimes, Sandbrink, Pohl.
Acquisition of data: Ascherio, Polman, Barkhof, Pleimes, Sandbrink, Pohl.
Analysis and interpretation of data: Ascherio, Munger, White, Köchert, Simon, Freedman, Hartung, Miller, Edan, Barkhof, Pleimes, Radü, Sandbrink, Kappos, Pohl.
Drafting of the manuscript: Ascherio.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ascherio, Munger, White, Köchert, Pleimes.
Obtained funding: Ascherio, Munger, Polman, Sandbrink.
Administrative, technical, and material support: Freedman, Hartung, Pleimes, Kappos.
Study supervision: Ascherio, Polman, Edan, Barkhof, Sandbrink, Kappos.
Conflict of Interest Disclosures: Dr Ascherio has received honoraria for speaking at scientific symposia by Roche, Sanofi-Aventis, Serono, and Almirall. Mr White has served as a consultant for and received financial compensation from Bayer Schering Pharma. Dr Köchert is a statistical consultant paid by Bayer Pharma AG. Dr Polman has received personal compensation from Biogen Idec, Bayer Schering Pharma AG, Teva Pharmaceutical Industries, Merck Serono, Novartis Pharmaceutical Corp, GlaxoSmithKline, Actelion Pharmaceuticals Ltd, UCB, and Roche for consulting services. The VU University Medical Center received financial support for research activities from Bayer Schering, Biogen Idec, Merck Serono, Teva, Novartis, GlaxoSmithKline, and Roche. Dr Freedman has received personal compensation and research support from Teva Pharmaceutical Industries, Merck Serono, Bayer Schering Pharma AG, Biogen-Dompé, and Genmab. Dr Hartung has received honoraria for consulting and speaking at symposia from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva, and Sanofi-Aventis, with approval by the rector of Heinrich-Heine University. Dr Miller has received honoraria and compensation through payments to University College London Institute of Neurology for advisory committee and/or consultancy advice in multiple sclerosis studies from Biogen Idec, GlaxoSmithKline, and Bayer Schering, as well as for work as editor of the Journal of Neurology. Dr Miller has received research grant support through the University College London Institute of Neurology for performing central magnetic resonance imaging analysis of multiple sclerosis trials from GlaxoSmithKline, Biogen Idec, and Novartis. Dr Montalban has received speaking honoraria and travel expenses for scientific meetings and has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Bayer, Biogen Idec, EMD, Genentech, Genzyme, Merck Serono, Neurotec, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, and Almirall. Dr Edan has received honoraria for lectures or consulting from Biogen Idec, Merck Serono, and Sanofi-Aventis and received personal compensation for serving on the BENEFIT scientific advisory board and for speaking from Bayer Schering Pharma AG. Dr Edan has also received research support from Serono through a grant to University Hospital to support a research program on magnetic resonance imaging in multiple sclerosis and from Teva through a grant to support a research program on anti-IBF neutralizing antibodies. Dr Barkhof has received compensation for consultancy from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche, and Teva, as well as has received research support from the Dutch Foundation for MS Research (a nongovernmental organization). Dr Pleimes is a salaried employee of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. Dr Pleimes owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. Dr Radü has received honoraria for serving as a speaker at scientific meetings and a consultant for Novartis, Biogen Idec, Merck Serono, and Bayer Schering. He has received financial support for research activities from Actelion, Basilea Pharmaceutica Ltd, Biogen Idec, Merck Serono, and Novartis. Dr Sandbrink is a salaried employee of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. Dr Sandbrink owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. Dr Kappos has lectured at medical conferences or in public and received honoraria, which have been exclusively used for funding research for his department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by nonrestricted grants from Acorda Therapeutics Inc, Actelion Pharmaceuticals Ltd, Allozyne, BaroFold, Bayer HealthCare Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, Boehringer Ingelheim, Eisai Inc, Elan, Genmab, GlaxoSmithKline, Merck Serono, MediciNova, Novartis, Sanofi-Aventis, Santhera Pharmaceuticals, Shire Plc, Roche, Teva, UCB, and Wyeth, as well as by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto Foundation, Novartis, and Roche Research Foundations. Dr Pohl is a salaried employee of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. Dr Pohl owns stock in Bayer AG, the owner of Bayer Pharma AG/Bayer HealthCare Pharmaceuticals. No other disclosures were reported.
Funding/Support: This study was supported by the National Institute of Neurological Diseases and Stroke and the National Multiple Sclerosis Society. The BENEFIT study was sponsored by Bayer.
Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the BENEFIT participants, Robert Ristuccia, PhD, for technical support, and Leslie Unger, BA, for administrative support. Dr Ristuccia is the medical director of Precept Medical Communications and did not receive compensation from a funding sponsor for his contribution. Ms Unger is with the Harvard School of Public Health; part of her institutional salary was covered by the National Institutes of Health grant that supported this research.
Create a personal account or sign in to: